ArticleScientific reports2026
Integrated bioinformatics approaches and expression assays identified a potential prognostic biomarker in oral squamous cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Research on prognostic factors for oral squamous cell carcinoma (OSCC) has revealed new therapeutic targets, with angiogenesis playing a key role in tumor development, invasion, and prognosis. However, reports on OSCC prognostic prediction construction based on angiogenesis factors are limited. Through bioinformatics analysis, we aimed to identify angiogenesis factors whose expression changes may be linked to OSCC prognosis. RNA sequencing, clinical data, and angiogenesis factor data were obtained from The Cancer Genome Atlas and Molecular Signatures Database. The characterized gene was selected and analyzed for correlations with clinicopathological features, prognosis, and cancer-associated fibroblasts infiltration using various databases. Further analyses included gene mutation, functional enrichment, and validation using clinical OSCC samples and tumor-bearing nude mice. Gene expression was assessed by western blotting, immunohistochemistry, immunofluorescence, and quantitative reverse transcription polymerase chain reaction. Epidermal growth factor (EGF) emerged as a key gene, showing significant upregulation in OSCC tissues compared to normal oral mucosa. Univariate and multivariate Cox regression analyses confirmed that high EGF expression correlates with poor overall survival and serves as an independent prognostic factor. EGF was also linked to cancer-associated fibroblast infiltration and can influence angiogenesis pathways. Our findings indicate that EGF may serve as a prognostic biomarker and potential therapeutic target for OSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.